Adamas Pharmaceuticals Inc.

NASDAQ: ADMSHealthcare / Drugs - Generic / USA
6.0000.00Vol 256 6581Y Perf -77.78%
Jul 22nd, 2019 16:00
BID6.00 ASK6.01
Open6.00 Previous Close6.00
Pre-Market- After-Trading6.00
 - -%  - -%
Target Price
14.43 
Analyst Rating
Moderate Buy 2.11
Potencial %
140.50 
Finscreener Ranking
★★★+ —    -
Insiders Trans % 3/6/12M
-100/-100/-71 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-100/-100/-35 
Growth Ranking
★★+     48.54
Insiders Shares Cnt. % 3/6/12M
-100/-100/-52 
Income Ranking
 —    -
Market Cap (mil)165 
Earnings Rating
Strong Buy
Price Range Ratio 52wk %
7.12 
Earnings Date
1st Aug 2019

Today's Price Range

5.906.10

52wk Range

4.2029.49

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
-0.17%
1 Month
9.09%
3 Months
-5.81%
6 Months
-30.31%
1 Year
-77.78%
3 Years
-61.32%
5 Years
-64.22%
10 Years
-

Name / TickerPriceChg.Chg.%
ADMS6.000.00000.00
AAPL207.224.63002.29
GOOG1 138.077.97000.71
MSFT138.431.81001.32
XOM75.070.08000.11
WFC46.480.45000.98
JNJ128.64-1.6700-1.28
FB202.323.96002.00
GE10.210.17001.69
JPM114.270.73000.64
Earnings HistoryEstimateReportedSurprise %
Q01 2019-1.13-1.084.42
Q04 2018-1.36-1.0622.06
Q03 2018-1.34-1.228.96
Q02 2018-1.41-1.2610.64
Q01 2018-1.38-1.352.17
Q04 2017-1.15-1.27-10.43
Q03 2017-1.03-1.04-0.97
Q02 2017-0.85-0.93-9.41
Earnings Per EndEstimateRevision %Trend
6/2019 QR-0.977.62Positive
9/2019 QR-0.938.82Positive
12/2019 FY-3.778.94Positive
12/2020 FY-2.42-8.52Negative
Next Report Date1st Aug 2019
Estimated EPS Next Report-0.97
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume256 658
Shares Outstanding (in ths.)27 533
Trades Count1 231
Dollar Volume1 327 826
Avg. Volume469 505
Avg. Weekly Volume336 031
Avg. Monthly Volume298 703
Avg. Quarterly Volume362 201
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (55.56 %)
5 (55.56 %)
5 (55.56 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (33.33 %)
3 (33.33 %)
3 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (11.11 %)
1 (11.11 %)
1 (11.11 %)
RatingModerate Buy
2.11
Moderate Buy
2.11
Moderate Buy
2.11

Adamas Pharmaceuticals Inc.

Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.

CEO: Gregory T. Went

Teplephone: +1 510 450-3500

Address: 1900 Powell Street, Emeryville 94608, CA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

38%63%

Bearish Bullish

50%50%

News